Silence Therapeutics (SLN)
13.06
+0.04 (0.31%)
Upcoming Events
Latest Headlines
William Blair Issues Conviction List for September
September 1, 2026 7:07 AM - StreetInsider
Silence Therapeutics closes $201M public offering of ADSs
August 14, 2026 4:55 PM - StreetInsider
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
August 14, 2026 4:55 PM - BizWire
Silence Therapeutics prices $175 million public offering at $13.50 per ADS
August 11, 2026 11:20 PM - StreetInsider
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
August 11, 2026 11:20 PM - BizWire
Silence Therapeutics (SLN) PT Raised to $32 at Morgan Stanley
August 11, 2026 9:09 AM - StreetInsider
Silence Therapeutics launches $150 million ADS public offering
August 10, 2026 4:01 PM - StreetInsider
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
August 10, 2026 4:01 PM - BizWire
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
August 10, 2026 10:40 AM - StreetInsider
Silence Therapeutics plc (SLN) Tops Q2 EPS by 5c
August 10, 2026 8:03 AM - StreetInsider
Silence Therapeutics' divesiran meets Phase 2 endpoints in blood cancer trial
August 10, 2026 7:30 AM - StreetInsider
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
August 10, 2026 7:30 AM - BizWire
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
August 10, 2026 7:15 AM - BizWire
Silence Therapeutics to discuss Phase 2 divesiran trial results
August 9, 2026 5:00 PM - StreetInsider
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
August 9, 2026 5:00 PM - BizWire
Form 8-K/A Silence Therapeutics For: Jul 10
July 16, 2026 5:21 PM - SEC Filing
Form SCHEDULE 13D/A Silence Therapeutics Filed by: Griffiths Richard Ian
July 8, 2026 7:01 AM - SEC Filing
Form 4 Silence Therapeutics For: Jun 29 Filed by: Griffiths Richard Ian
July 7, 2026 9:10 AM - SEC Filing
Cantor Fitzgerald Starts Silence Therapeutics (SLN) at Overweight
June 24, 2026 6:05 AM - StreetInsider
Form 8-K Silence Therapeutics For: Jun 23
June 23, 2026 4:36 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Silence Therapeutics (SLN)
June 17, 2026 6:49 AM - StreetInsider
Form 8-K Silence Therapeutics For: Jun 16
June 16, 2026 5:00 PM - SEC Filing
Full Article List
